Parelsnoer IBD

PSI-IBD - Parelsnoer Inflammatory Bowel Diseases

National biobank to facilitate clinically relevant multi-omics research in patients with IBD. Cohort
National biobank to facilitate clinically relevant multi-omics research in patients with IBD.
Inflammatory Bowel Diseases (IBD) are diseases characterized by inflammation of the gastrointestinal tract, including Crohn’s disease and ulcerative colitis.

Affecting approximately 100.000 persons in the Netherlands alone, the prevalence of IBD is rising. Its cause is multifactorial, involving a complex interplay between host genetics, environmental factors including the diet and dysregulated immune responses towards the gut microbiome.

PSI-IBD aims to:

  • gain further knowledge of the complex etiology of development and course of IBD;  
  • search for predictors of treatment response;  
  • use multi-omics data research of large groups of patients and translate its findings to personalized treatment of individual patients.

How PSI-IBD benefits to society

IBD is one of the immune mediated inflammatory diseases (IMID) that is showing a rising incidence worldwide. Therefore, exploration of (modifiable) factors involved in disease development as well as its course is crucial for future preventative strategies. Also, research focused on prediction of medication efficacy instead of the current trial-and-error treatment strategy, will potentially lead to better disease management (i.e. shorter time to remission) and decrease in health care costs.


Small profile picture of K. van der Sloot
Kim van der Sloot Postdoctoral researcher and resident in training, gastroenterology and hepatology.

University Medical Center Groningen (UMCG)
Parelsnoer Inflammatory Bowel Diseases  (PSI-IBD)
PO Box 30.001
9700 RB Groningen
The Netherlands

Visiting address
University Medical Center Groningen (UMCG)
Department of Gastroenterology and Hepatology
Hanzeplein 1
9713 GZ Groningen

More information visite our website